ABIONYX Pharma SA (ABNX.PA)
EUR 1.25
(2.46%)
EUR 1.25
(2.46%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.39 Million EUR | -15.52% |
| 2022 | 4.01 Million EUR | -19.06% |
| 2021 | 4.95 Million EUR | 20558.33% |
| 2020 | 24 Thousand EUR | -97.97% |
| 2019 | 1.18 Million EUR | -78.5% |
| 2018 | 5.5 Million EUR | -11.57% |
| 2017 | 6.22 Million EUR | -7.88% |
| 2016 | 6.75 Million EUR | 10.85% |
| 2015 | 6.09 Million EUR | 22.08% |
| 2014 | 4.99 Million EUR | 23.32% |
| 2013 | 4.04 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 1.7 Million EUR | 0.0% |
| 2023 Q1 | 3.96 Million EUR | -1.3% |
| 2023 Q3 | 3.08 Million EUR | -27.74% |
| 2023 Q4 | 3.39 Million EUR | 10.03% |
| 2023 FY | 3.39 Million EUR | -15.52% |
| 2023 Q2 | 4.26 Million EUR | 7.65% |
| 2022 Q2 | 4.49 Million EUR | 9.75% |
| 2022 Q3 | 3.63 Million EUR | -19.12% |
| 2022 FY | 4.01 Million EUR | -19.06% |
| 2022 Q1 | 4.09 Million EUR | -17.43% |
| 2022 Q4 | 4.01 Million EUR | 10.43% |
| 2021 Q4 | 4.95 Million EUR | 8.8% |
| 2021 FY | 4.95 Million EUR | 20558.33% |
| 2021 Q3 | 4.55 Million EUR | 2661.82% |
| 2021 Q2 | 165 Thousand EUR | 50.0% |
| 2021 Q1 | 110 Thousand EUR | 358.33% |
| 2020 Q1 | 1.1 Million EUR | -7.02% |
| 2020 Q3 | - EUR | -100.0% |
| 2020 Q4 | 24 Thousand EUR | 0.0% |
| 2020 Q2 | 1.15 Million EUR | 4.91% |
| 2020 FY | 24 Thousand EUR | -97.97% |
| 2019 Q4 | 1.18 Million EUR | 5.34% |
| 2019 Q3 | 1.12 Million EUR | -10.02% |
| 2019 Q2 | 1.24 Million EUR | 4.87% |
| 2019 Q1 | 1.19 Million EUR | -78.38% |
| 2019 FY | 1.18 Million EUR | -78.5% |
| 2018 FY | 5.5 Million EUR | -11.57% |
| 2018 Q4 | 5.5 Million EUR | 0.0% |
| 2018 Q3 | 5.5 Million EUR | -15.25% |
| 2018 Q2 | 6.49 Million EUR | -2.99% |
| 2018 Q1 | 6.69 Million EUR | 7.55% |
| 2017 Q3 | 6.22 Million EUR | 13.87% |
| 2017 Q2 | 5.46 Million EUR | -3.53% |
| 2017 Q1 | 5.66 Million EUR | -16.14% |
| 2017 FY | 6.22 Million EUR | -7.88% |
| 2017 Q4 | 6.22 Million EUR | 0.0% |
| 2016 Q2 | 6.08 Million EUR | -7.6% |
| 2016 FY | 6.75 Million EUR | 10.85% |
| 2016 Q1 | 6.58 Million EUR | 8.02% |
| 2016 Q3 | 7.05 Million EUR | 15.98% |
| 2016 Q4 | 6.75 Million EUR | -4.25% |
| 2015 Q3 | 6.09 Million EUR | 9.06% |
| 2015 Q1 | - EUR | -100.0% |
| 2015 Q4 | 6.09 Million EUR | 0.0% |
| 2015 FY | 6.09 Million EUR | 22.08% |
| 2015 Q2 | 5.58 Million EUR | 0.0% |
| 2014 FY | 4.99 Million EUR | 23.32% |
| 2014 Q3 | 4.99 Million EUR | 0.0% |
| 2014 Q4 | 4.99 Million EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2013 FY | 4.04 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIVAX Société Anonyme | 55.46 Million EUR | 93.888% |
| Adocia SA | 13.08 Million EUR | 74.098% |
| Aelis Farma SA | 4.03 Million EUR | 16.048% |
| Biophytis S.A. | 8.27 Million EUR | 59.008% |
| Advicenne S.A. | 17.42 Million EUR | 80.545% |
| genOway Société anonyme | 7.23 Million EUR | 53.134% |
| IntegraGen SA | 1.12 Million EUR | -201.404% |
| Medesis Pharma S.A. | 1.2 Million EUR | -182.5% |
| Neovacs S.A. | 650 Thousand EUR | -421.538% |
| NFL Biosciences SA | 62.17 Thousand EUR | -5352.44% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 22.185% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -24.777% |
| Sensorion SA | 2.86 Million EUR | -18.168% |
| Theranexus Société Anonyme | 3.64 Million EUR | 6.945% |
| TME Pharma N.V. | 1.16 Million EUR | -190.738% |
| Valbiotis SA | 6.87 Million EUR | 50.712% |
| TheraVet SA | 1.15 Million EUR | -192.275% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | 62.325% |
| argenx SE | 18.1 Million EUR | 81.276% |
| BioSenic S.A. | 28.16 Million EUR | 87.962% |
| Celyad Oncology SA | 902 Thousand EUR | -275.831% |
| DBV Technologies S.A. | 13.01 Million USD | 73.96% |
| Galapagos NV | 9.59 Million EUR | 64.673% |
| Genfit S.A. | 70.17 Million EUR | 95.169% |
| GeNeuro SA | 7.73 Million EUR | 56.189% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | 35.965% |
| Innate Pharma S.A. | 39.89 Million EUR | 91.502% |
| Inventiva S.A. | 37.4 Million EUR | 90.938% |
| MaaT Pharma SA | 14.07 Million EUR | 75.915% |
| MedinCell S.A. | 58.96 Million EUR | 94.25% |
| Nanobiotix S.A. | 50.56 Million EUR | 93.296% |
| Onward Medical N.V. | 16.87 Million EUR | 79.91% |
| Oryzon Genomics S.A. | 13.68 Million EUR | 75.232% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | 92.598% |
| Oxurion NV | 12.33 Million EUR | 72.515% |
| Pharming Group N.V. | 155.29 Million EUR | 97.817% |
| Poxel S.A. | 46.9 Million EUR | 92.772% |
| GenSight Biologics S.A. | 18.42 Million EUR | 81.604% |
| Transgene SA | 1.25 Million EUR | -169.69% |
| Financière de Tubize SA | 79.2 Million EUR | 95.72% |
| UCB SA | 3.03 Billion EUR | 99.888% |
| Valneva SE | 208.81 Million EUR | 98.377% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -8821.053% |